Axsome Therapeutics (AXSM) Operating Expenses (2015 - 2026)

Axsome Therapeutics has disclosed Operating Expenses across 12 years of filings, most recently posting $254.6 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $254.6 million, up 42.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $881.4 million (up 25.48% YoY), and the FY2025 annual result was $805.3 million, up 20.86% from the prior year.
• Operating Expenses came in at $254.6 million for Q1 2026 at Axsome Therapeutics, up from $223.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $254.6 million in Q1 2026 to a low of $38.3 million in Q1 2022.
• The 5-year median for Operating Expenses is $165.2 million (2024), against an average of $144.6 million.
• Across the five-year window, Operating Expenses surged 163.65% in 2023 and gained 12.71% in 2024, its largest moves.
• Axsome Therapeutics' Operating Expenses stood at $84.3 million in 2022, then jumped by 101.45% to $169.8 million in 2023, then grew by 12.71% to $191.4 million in 2024, then rose by 16.5% to $223.0 million in 2025, then climbed by 14.17% to $254.6 million in 2026.
• The last three Operating Expenses figures came in at $254.6 million (Q1 2026), $223.0 million (Q4 2025), and $217.1 million (Q3 2025), per Business Quant data.